A Phase 1 study of KITE-753 or KITE-363 in patients with relapsed/refractory B-cell lymphoma: Initial safety and preliminary efficacy of KITE-753 and updated results of KITE-363

Lead author: Saurabh Dahiya et al  

Phase 2 registrational study of anitocabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma: Updated results from iMMagine--1

Presenting author: Krina Patel et al

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Lead author: Suzanne van Dorp et al

Blood and CSF metabolomics identifies tryptophan catabolism and polyamine synthesis as drivers of CAR T-cell-associated neurotoxicity 

Lead author: Soumya Poddar et al

Double-dose axicabtagene ciloleucel (Axi-Cel-2) as second-line therapy for high-risk relapsed or refractory large B-cell lymphoma (r/rLBCL): Interim results from a Phase 1b study  

Presenting author: Dasom (Caroline) Lee et al 

Patient journey with axicabtagene ciloleucel for relapsed or refractory large B cell lymphoma in Canada: Manufacturing experience and impact of patient location to treatment centre

Presenting author:  Natasha Kekre et al

Diffuse large B cell lymphoma in Brazil: Understanding the patient journey to improve healthcare assistance.

Presenting author: Thais Fischer et al 

Endogenous regulation of inflammatory response as a determinant of durable remission without stem cell transplant following brexucabtagene autoleucel (Brexu-cel) therapy in ALL  

Presenting author: Jae Park et al

Two-Year Update of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) With Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Had Not Received Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy  

Presenting author: Tom van Meerten et al

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Presenting author: Amer Beitinjaneh et al

Estimating the survival impact of not receiving CAR T-cell (CAR T) therapy when eligible in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the United States (US)

Presenting author: Frederick Locke et al

Real-world treatment patterns and survival outcomes in second and third line settings in large B-cell lymphoma (LBCL)

Presenting author: Joseph McGuirk et al

Real-world healthcare resource utilization (HCRU) following CAR T-cell therapy in US patients treated in newly authorized treatment centers

Presenting author: Olalekan Oluwole et al

Surrogate endpoints as prognostic factors for long-term outcomes among patients receiving axicabtagene ciloleucel in frontline high-risk large B cell lymphoma

Presenting author: Sattva Neelapu et al

US cost consequence and time toxicity model for advanced therapies in the treatment for Relapsed/Refractory third-line or later diffuse large B-cell lymphoma: A comparison of axicabtagene ciloleucel with bispecific antibodies

Presenting author: Olalekan Oluwole et al

Real-world effectiveness and safety outcomes by age, comorbidity, frailty, and treatments prior to infusion in relapsed or refractory (R/R) follicular lymphoma patients treated with axicabtagene ciloleucel  

Presenting author: Aung Tun et al

Outcomes of inpatient and outpatient chimeric antigen receptor T-cell therapy (CAR T) in newly authorized treatment centers (ATCs) in the United States (US)

Presenting author: Olalekan Oluwole et al

Visualizing geographic variation and systemic inequities of disease burden and CAR T-cell therapy access in multiple myeloma in the US  

Presenting author: Brandon Blue et al

Pre-treatment CD19 antigen density and multi-antigen profiling by calibrated quantitative flow cytometry correlates with CAR T efficacy in LBCL  

Presenting author: Jay Spiegel et al 

Axi-cel delivers similar outcomes regardless of ASCT-eligibility in second line R/R LBCL: Combined data from ZUMA-7 and ALYCANTE

Presenting author: Roch Houot et al

The fast off-rate of anito-cel's D-Domain binder contributes to its distinctive pharmacology profile in preclinical models of multiple myeloma

Presenting author: Kevin Hart et al